Zu den Inhalten springen


German Cancer Consortium - Deutsches Konsortium Translationale Krebsforschung

The German Cancer Consortium (DKTK) is a joint initiative involving the German Federal Ministry of Education and Research (BMBF), participating German states, German Cancer Aid, and the German Cancer Research Center (DKFZ). It was established in October 2012 as one of six German Health Research Centers (DZGs).

Within DKTK, cancer researchers and medical practitioners collaborate closely at eight locations across Germany: Berlin, Dresden, Essen/Düsseldorf, Frankfurt/Mainz, Freiburg, Heidelberg, Munich, and Tübingen.

The aim is to speed up the transfer to clinical practice of new diagnostic and treatment approaches. Translating innovations quickly from basic research into clinical practice is the core task of DKTK.

To learn more about DKTK translational research programs and platforms, opportunities for young scientists, events, and news, visit the DKTK webpage.

DKTK has prioritized five major challenges facing cancer research today:

  • Challenge 1: Molecular profiling-based diagnosis and therapy
  • Challenge 2: Early diagnosis of cancer and detection of minimal residual disease
  • Challenge 3: Tumor heterogeneity and resistance
  • Challenge 4: Immunotherapy beyond checkpoint inhibition
  • Challenge 5: Turning big data into smart data

The DKTK Freiburg Partner Site

DKTK Freiburg tackles the five major challenges defined by the DKTK consortium and addresses them by focusing on three priority areas (PA) with special expertise in Freiburg:


-- Logo: © dkfz.de

Prof. Dr. Christoph Peters
Tumorzentrum Freiburg CCCF
Phone: +49-761-270-71500
Hugstetter Str. 49
79106 Freiburg


Institute of Molecular Medicine and Cell Research
University of Freiburg
Stefan-Meier-Str. 17
79104 Freiburg
Phone: +49-761-203-9600/9601

Dr. Anja Hernández
Deutsches Krebsforschungszentrum (DKFZ)
Im Neuheimer Feld 280
69120 Heidelberg
++49 (0)761 270 22810